NASDAQ:AXSM - Axsome Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $134.36
  • Forecasted Upside: 88.24 %
  • Number of Analysts: 12
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$71.38
▲ +0.68 (0.96%)
1 month | 3 months | 12 months
Get New Axsome Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXSM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$134.36
▲ +88.24% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $134.36, with a high forecast of $210.00 and a low forecast of $66.00. The average price target represents a 88.24% upside from the last price of $71.38.
Buy
The current consensus among 12 contributing investment analysts is to buy stock in Axsome Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 2 sell ratings
10/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2020William BlairReiterated RatingBuyLow
i
Rating by Myles Minter at William Blair
9/29/2020Bank of AmericaInitiated CoverageUnderperform$66.00High
i
9/29/2020BofA SecuritiesInitiated CoverageUnderperform$66.00High
i
9/10/2020Morgan StanleyInitiated CoverageOverweight$102.00Low
i
9/4/2020William BlairReiterated RatingBuyN/A
i
Rating by Myles Minter at William Blair
8/21/2020William BlairReiterated RatingBuyLow
i
Rating by Myles Minter at William Blair
8/10/2020William BlairReiterated RatingBuyMedium
i
Rating by Myles Minter at William Blair
8/6/2020HC WainwrightReiterated RatingBuy$210.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/14/2020HC WainwrightReiterated RatingBuy$210.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/30/2020HC WainwrightReiterated RatingBuy$210.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/28/2020GuggenheimBoost Price TargetIn-Line ➝ Buy$158.00 ➝ $200.00Medium
i
Rating by Yatin Suneja at Guggenheim
4/28/2020HC WainwrightBoost Price TargetBuy$200.00 ➝ $210.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/27/2020Cantor FitzgeraldBoost Price TargetOverweight$125.00 ➝ $131.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
4/27/2020LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$165.00 ➝ $186.00Low
i
4/27/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$145.00 ➝ $200.00High
i
4/14/2020CowenInitiated CoverageOutperform$95.00High
i
4/6/2020William BlairReiterated RatingBuyHigh
i
Rating by Myles Minter at William Blair
4/6/2020HC WainwrightReiterated RatingBuy$200.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/16/2020HC WainwrightReiterated RatingBuy$200.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/24/2020HC WainwrightReiterated RatingBuy$200.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/28/2020HC WainwrightReiterated RatingBuy$200.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/21/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by Ram Selvaraju at HC Wainwright
1/14/2020LADENBURG THALM/SH SHReiterated RatingBuy$139.00 ➝ $165.00Medium
i
1/2/2020SunTrust BanksBoost Price TargetBuy$140.00Medium
i
12/30/2019BTIG ResearchBoost Price TargetBuy$97.00Medium
i
12/30/2019LADENBURG THALM/SH SHBoost Price TargetBuy$139.00 ➝ $165.00Low
i
12/30/2019Cantor FitzgeraldReiterated RatingOverweight$104.00 ➝ $125.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
12/24/2019HC WainwrightReiterated RatingBuy$170.00 ➝ $200.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
12/17/2019SunTrust BanksBoost Price TargetBuy$100.00High
i
12/17/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$97.00High
i
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$125.00Medium
i
Rating by Danielle Brill at Piper Jaffray Companies
12/16/2019Cantor FitzgeraldBoost Price TargetOverweight$55.00 ➝ $104.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/4/2019GuggenheimBoost Price Target$65.00 ➝ $48.00High
i
12/4/2019SunTrust BanksReiterated RatingBuy ➝ Positive$60.00High
i
12/4/2019BTIG ResearchReiterated RatingBuy ➝ Positive$48.00Medium
i
12/3/2019Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$45.00 ➝ $55.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
11/26/2019Cantor FitzgeraldReiterated RatingBuy$45.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
10/17/2019HC WainwrightReiterated RatingBuy$30.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2019GuggenheimInitiated CoverageBuy$48.00High
i
9/18/2019William BlairInitiated CoverageOutperform$48.00Low
i
Rating by M. Minter at William Blair
6/24/2019HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/28/2019Cantor FitzgeraldReiterated RatingOverweight$25.00 ➝ $35.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
5/28/2019SunTrust BanksInitiated CoverageBuy ➝ BuyLow
i
5/23/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $30.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/15/2019HC WainwrightReiterated RatingBuy ➝ Average$18.00 ➝ $23.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/8/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00Medium
i
Rating by M. Goodman at SVB Leerink LLC
3/28/2019BTIG ResearchBoost Price TargetBuy$25.00Low
i
3/26/2019HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/21/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $25.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
3/15/2019HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $18.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/15/2019Cantor FitzgeraldBoost Price TargetOverweight$13.00 ➝ $16.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
3/5/2019HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/31/2019HC WainwrightReiterated RatingBuy$15.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/14/2019HC WainwrightReiterated RatingBuy$15.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/8/2019BTIG ResearchBoost Price TargetBuy$20.00High
i
1/7/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$34.00 ➝ $45.00High
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
1/7/2019HC WainwrightBoost Price TargetBuy$15.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/10/2018Cantor FitzgeraldSet Price TargetBuy$16.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/5/2018HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/15/2018Cantor FitzgeraldInitiated CoverageOverweight$16.00High
i
Rating by C. Duncan at Cantor Fitzgerald
10/24/2018HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/17/2018LADENBURG THALM/SH SHSet Price TargetBuy$34.00 ➝ $5.00High
i
10/9/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/21/2018HC WainwrightReiterated RatingBuy$10.00Low
i
Rating by R. Selvaraju at HC Wainwright
6/7/2018HC WainwrightInitiated CoverageBuy$10.00High
i
Rating by R. Selvaraju at HC Wainwright
4/29/2018BTIG ResearchReiterated RatingBuy$16.00High
i
12/1/2017Cantor FitzgeraldSet Price TargetBuy$13.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
7/26/2017LADENBURG THALM/SH SHReiterated RatingBuy$28.00 ➝ $31.00High
i
6/20/2017AegisReiterated RatingBuy$20.00High
i
Rating by D. Yang at Aegis
5/25/2017AegisReiterated RatingBuy$20.00Medium
i
Rating by D. Yang at Aegis
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00High
i
3/21/2017AegisReiterated RatingBuyHigh
i
Rating by D. Yang at Aegis
3/8/2017Cantor FitzgeraldSet Price TargetBuy$13.00Low
i
Rating by Chiara Russo at Cantor Fitzgerald
2/14/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
1/11/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
1/3/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
11/15/2016Cantor FitzgeraldReiterated RatingBuy$13.00N/A
i
Rating by chiara russo at Cantor Fitzgerald
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/A
i
Rating by jonathan aschoff at Brean Capital
8/21/2016Brean CapitalSet Price TargetBuy$29.00N/A
i
Rating by jonathan aschoff at Brean Capital
8/10/2016Cantor FitzgeraldSet Price TargetBuy$13.00N/A
i
Rating by chiara russo at Cantor Fitzgerald
8/10/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
5/12/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
5/12/2016Brean CapitalReiterated RatingBuy$29.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
5/3/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
3/30/2016LADENBURG THALM/SH SHBoost Price TargetBuy$25.00 ➝ $27.00N/A
i
3/29/2016Cantor FitzgeraldReiterated RatingBuy$13.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
3/28/2016Brean CapitalInitiated CoverageBuy$29.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
3/17/2016Cantor FitzgeraldReiterated RatingBuy$13.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
12/17/2015Brean CapitalInitiated CoverageBuy$29.00N/A
i
12/15/2015Cantor FitzgeraldInitiated CoverageBuy$13.00N/A
i
Rating by C. Russo at Cantor Fitzgerald
12/14/2015LADENBURG THALM/SH SHInitiated CoverageBuy$25.00N/A
i
(Data available from 10/26/2015 forward)
Axsome Therapeutics logo
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Read More

Today's Range

Now: $71.38
$69.90
$71.90

50 Day Range

MA: $74.34
$68.34
$83.06

52 Week Range

Now: $71.38
$20.48
$109.94

Volume

7,609 shs

Average Volume

673,178 shs

Market Capitalization

$2.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8